Pharming (PHAR) Other Non-Current Liabilities (2025 - 2026)
Pharming (PHAR) posted Other Non-Current Liabilities of $675000.0 for Q1 2026, down 43.13% on a QoQ basis from $1.2 million in Q4 2025.
Pharming (PHAR) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
Pharming's Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $675000.0 for Q1 2026.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $675000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $675000.0 (changed N/A YoY) and the FY2025 annual result came in at $1.2 million, changed N/A from the prior year.
- Other Non-Current Liabilities was $675000.0 for Q1 2026 at Pharming, down from $1.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.2 million in Q4 2025 and bottomed at $675000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Pharming | 9.02 Bn | 8.96 Bn | 65.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 675,000.00 |
| Dec 31, 2025 | 1.19 Mn |